Seeing Is Believing
Currently out of the existing stock ratings of Robert Leboyer, 14 are a BUY (87.5%), 2 are a HOLD (12.5%).
Analyst Robert Leboyer, currently employed at NOBLE CAPITAL, carries an average stock price target met ratio of 85.71% that have a potential upside of 64.79% achieved within 478 days.
Robert Leboyer’s has documented 30 price targets and ratings displayed on 8 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on TNXP, Tonix Pharmaceuticals Holding Corp at 19-Mar-2025.
Analyst best performing recommendations are on BNTC (BENITEC BIOPHARMA LTD ADR).
The best stock recommendation documented was for BNTC (BENITEC BIOPHARMA LTD ADR) at 4/20/2020. The price target of $238 was fulfilled within 1 day with a profit of $15.98 (7.2%) receiving and performance score of 71.98.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold
2 years 7 months 27 days ago
(15-Feb-2023)
0/1 (0%)
$242.25 (224.83%)
Hold
$6
$5.15 (605.88%)
2 years 9 months 28 days ago
(15-Dec-2022)
1/1 (100%)
$-4.98 (-45.36%)
1
Buy
$5
$4.11 (461.80%)
2 years 11 months 11 days ago
(02-Nov-2022)
0/1 (0%)
$3.97 (385.44%)
Buy
$7
$-0.86 (-10.94%)
$12
2 years 11 months 11 days ago
(02-Nov-2022)
2/2 (100%)
$-25.13 (-72.62%)
132
Buy
3 years 2 months 10 days ago
(03-Aug-2022)
0/1 (0%)
$155.75 (42.18%)
What Year was the first public recommendation made by Robert Leboyer?